Drug intelligence / Profile preview

CD147 shRNA

Development stage
Preclinical
Modality
Viral-delivered RNAi → In Vivo RNAi → Gene Silencing → Gene Therapies, RNA Therapeutics → Nucleic Acid Therapeutics
Administration
Intravenous, Intratumoral, Ex Vivo
01

Overview

CD147 shRNA is a short hairpin RNA (shRNA) designed to specifically silence the expression of the CD147 gene, also known as Basigin or Extracellular Matrix Metalloproteinase Inducer (EMMPRIN), through the mechanism of RNA interference (RNAi). CD147 is a transmembrane glycoprotein that plays a crucial role in various physiological and pathological processes, including tumor progression, metastasis, angiogenesis, and cellular glycolysis. By introducing shRNA molecules that are complementary to CD147 messenger RNA (mRNA), the shRNA is processed within the cell to trigger the degradation of the target mRNA, thereby preventing the translation of the CD147 protein. This downregulation of CD147 protein expression aims to inhibit its pro-tumorigenic functions, such as inducing matrix metalloproteinases (MMPs), promoting cell proliferation and invasion, and enhancing glycolysis in cancer cells. CD147 shRNA is primarily investigated as a therapeutic approach for various cancers where CD147 is overexpressed and contributes to disease pathology.

Other names
Basigin shRNAEMMPRIN shRNA
02

Targets

BSG (Basigin)

Beyond the preview

Go deeper on CD147 shRNA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on CD147 shRNA.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call